Margaret A. Tempero, MD

Professor of Medicine
Department of Medicine
Division of Hematology and Oncology
UCSF Helen Diller Family Comprehensive Cancer Center
San Francisco, California

Dr. Margaret Tempero received her medical degree from the University of Nebraska where she was also a medical oncology/hematology fellow. She is director of the UCSF Pancreas Center, and leader of the Pancreas Cancer Program at the Helen Diller Family Comprehensive Cancer Center (HDFCCC) in San Francisco.

Dr. Tempero has extensive experience in scientific review and administration, training, and oversight. She serves as chair of the NCCN Guidelines Panel on Pancreatic Cancer, and on the Pancreatic Cancer Task Force for the NCI Intergroup, was founding chair of the NCI Clinical Oncology Study Section (CONC), and served as chair of the NCI Board of Scientific Counselors Subcommittee A. She is, or has been, on the scientific advisory boards of the Lustgarten Foundation, Pancreatic Cancer Action Network, V Foundation, Alberta Canada Cancer Board, and the EORTC. In addition, Dr. Tempero has served as president of the ASCO Board of Directors and recently served on the Oncology Drug Advisory Committee for the FDA and as deputy director and director of research programs at HDFCCC.

Dr. Tempero’s research career has focused on pancreatic ductal adenocarcinoma, especially in the area of investigational therapeutics. She was a pioneer in the use of antibody-based therapies and helped develop the fixed-dose rate concept for gemcitabine.
Last modified: July 18, 2017

Partners in Pancreatic Cancer would like to recognize and thank Celgene Corporation
for their educational support of PartnersinPancreaticCancer.com.

©2017 MediCom Worldwide, Inc. All rights reserved